钠-葡萄糖共转运蛋白2抑制剂在心力衰竭中的作用机制研究进展  

Research progress on the mechanism of sodium-glucose cotransporter 2 inhibitors in heart failure

作　　者：朱琛颖[1] 王书琦 韩薇 Zhu chenying;Wang Shuqi;Han Wei(Shanghai East Hospital of Tongji University,Shanghai 200120,China;Shanxi Bethune Hospital,Taiyuan 030032,China)

机构地区：[1]同济大学附属上海市东方医院,上海200120 [2]山西白求恩医院,太原030032

出　　处：《中华心力衰竭和心肌病杂志（中英文）》2023年第2期109-114,共6页Chinese Journal of Heart Failure and Cardiomyopathy

基　　金：上海市浦东新区卫生系统重点学科建设资助(PWZxk2022-20)。

摘　　要：心力衰竭(心衰)是各种心脏疾病的严重表现或晚期阶段,死亡率和再住院率居高不下。现有研究证据表明,钠-葡萄糖共转运蛋白2(sodium-glucose cotransporter 2 inhibitors,SGLT2)抑制剂可以显著降低心衰患者的心血管死亡和再住院率。但其在心衰中的作用机制目前尚不明确。本文将从SGLT2抑制剂在心衰中作用的证据出发,对其在心衰中的作用机制和潜在获益进行梳理。Heart failure(HF),a complex cardiac syndrome,is associated with high rates of hospitalization and mortality.Recent trials have demonstrated that sodium-glucose cotransporter 2(SGLT2)inhibitor reduced the rate of hospital readmissions and the risk of cardiovascular death in patients with HF,but the potential mechanisms of action still need to be further elucidated.This paper will review the evidence in SGLT2 inhibitor trials and discuss the underlying mechanisms of benefits in patients with HF.

关 键 词：心力衰竭 钠-葡萄糖共转运蛋白2抑制剂 心脏保护机制 

分 类 号：R541.6[医药卫生—心血管疾病]